Bal Pharma Limited (NSE:BALPHARMA) — Market Cap & Net Worth
Market Cap & Net Worth: Bal Pharma Limited (BALPHARMA)
Bal Pharma Limited (NSE:BALPHARMA) has a market capitalization of $17.64 Million (Rs1.63 Billion) as of September 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #25599 globally and #1412 in its home market, demonstrating a 10.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bal Pharma Limited's stock price Rs102.46 by its total outstanding shares 15920872 (15.92 Million). Also see BALPHARMA total asset value for a full breakdown of the balance sheet.
Bal Pharma Limited Market Cap History: 2015 to 2026
Bal Pharma Limited's market capitalization history from 2015 to 2026. Data shows growth from $18.95 Million to $17.64 Million (2.87% CAGR). Also see BALPHARMA cash flow metrics for how efficiently the company converts equity into cash flow.
Bal Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bal Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Bal Pharma Limited (BALPHARMA) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Bal Pharma Limited's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.28x
Bal Pharma Limited's market cap is 0.28 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $17.75 Million | $2.29 Billion | $19.86 Million | 0.01x | 0.89x |
| 2018 | $12.81 Million | $2.09 Billion | $27.82 Million | 0.01x | 0.46x |
| 2019 | $6.82 Million | $2.25 Billion | $37.88 Million | 0.00x | 0.18x |
| 2020 | $9.33 Million | $1.71 Billion | -$122.18 Million | 0.01x | N/A |
| 2021 | $17.70 Million | $2.47 Billion | $47.42 Million | 0.01x | 0.37x |
| 2022 | $15.39 Million | $2.81 Billion | $56.12 Million | 0.01x | 0.27x |
| 2023 | $17.07 Million | $3.04 Billion | $25.72 Million | 0.01x | 0.66x |
| 2024 | $21.11 Million | $3.39 Billion | $73.92 Million | 0.01x | 0.29x |
| 2025 | $12.62 Million | $3.03 Billion | $72.15 Million | 0.00x | 0.17x |
| 2026 | $17.64 Million | $3.12 Billion | $62.84 Million | 0.01x | 0.28x |
Competitor Companies of BALPHARMA by Market Capitalization
Companies near Bal Pharma Limited in the global market cap rankings as of September 19, 2026. Review BALPHARMA intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bal Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Bal Pharma Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Bal Pharma Limited's market cap moved from $18.95 Million to $ 17.64 Million, with a yearly change of 2.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs17.64 Million | +39.74% |
| 2025 | Rs12.62 Million | -40.21% |
| 2024 | Rs21.11 Million | +23.66% |
| 2023 | Rs17.07 Million | +10.92% |
| 2022 | Rs15.39 Million | -13.02% |
| 2021 | Rs17.70 Million | +89.63% |
| 2020 | Rs9.33 Million | +36.77% |
| 2019 | Rs6.82 Million | -46.74% |
| 2018 | Rs12.81 Million | -27.84% |
| 2017 | Rs17.75 Million | +23.07% |
| 2016 | Rs14.42 Million | -23.88% |
| 2015 | Rs18.95 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Bal Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $17.64 Million USD |
| MoneyControl | $17.64 Million USD |
| MarketWatch | $17.64 Million USD |
| marketcap.company | $17.64 Million USD |
| Reuters | $17.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more